RVL Pharmaceuticals PLCNASDAQ:RVLP
- LAST PRICE1.0500
- TODAY'S CHANGE (%)0.0300 (2.9412%)
- Bid / Lots0.9950/ 50
- Ask / Lots1.1000/ 6
- Open / Previous Close1.0000 / 1.0200
- Day Range
- 52 Week Range
- Volume16,195
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RVLP |
|---|---|---|
| 09:32 ET | 553 | 1 |
| 09:59 ET | 1491 | 1.09 |
| 10:03 ET | 500 | 1.0501 |
| 10:14 ET | 1300 | 1.08 |
| 10:28 ET | 100 | 1.04 |
| 10:42 ET | 100 | 1.04 |
| 11:00 ET | 1000 | 1.06 |
| 11:08 ET | 1436 | 1.07 |
| 11:15 ET | 100 | 1.02 |
| 11:45 ET | 100 | 1.04 |
| 12:14 ET | 1500 | 1.03 |
| 12:18 ET | 385 | 1.0399 |
| 12:34 ET | 100 | 1.03 |
| 01:08 ET | 100 | 1.03 |
| 01:26 ET | 100 | 1.03 |
| 01:37 ET | 2300 | 1.04 |
| 02:29 ET | 150 | 1.0365 |
| 03:41 ET | 100 | 1.03 |
| 03:45 ET | 100 | 1.03 |
| 03:48 ET | 1000 | 1.0363 |
| 03:50 ET | 600 | 1.04 |
| 03:52 ET | 100 | 1.03 |
| 03:59 ET | 763 | 1.05 |
Mar 20, 2023
BRIEF-RVL Pharmaceuticals Posts Qtrly Loss Per Share Of $0.18, from 7:42AM ET on Monday Mar 20, 2023 by Thomson Reuters
7:42AM ET on Monday Mar 20, 2023 by Thomson Reuters-- Earnings Flash (RVLP) RVL PHARMACEUTICALS Posts Q4 Revenue $9.8M, vs. Street Est of $12.5M, from 6:52AM ET on Monday Mar 20, 2023 by MT Newswires
6:52AM ET on Monday Mar 20, 2023 by MT NewswiresRVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Commercial Update, from 6:50AM ET on Monday Mar 20, 2023 by GlobeNewswire
6:50AM ET on Monday Mar 20, 2023 by GlobeNewswire
Mar 15, 2023
RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Commercial Update, from 6:50AM ET on Wednesday Mar 15, 2023 by GlobeNewswire
6:50AM ET on Wednesday Mar 15, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
RVL Pharmaceuticals PLC | 101.3M | -1.9x | --- |
Affimed NV | 102.4M | -1.1x | --- |
Cidara Therapeutics Inc | 121.7M | -2.2x | --- |
G1 Therapeutics Inc | 134.3M | -0.8x | --- |
Mereo Biopharma Group PLC | 103.7M | -0.1x | --- |
Champions Oncology Inc | 56.3M | -18.5x | --- |
Company Information
RVL Pharmaceuticals plc is a specialty pharmaceutical company. The Company is focused on the commercialization of UPNEEQ, or RVL-1201 (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. It is focused on growing Upneeq with eye care and medical aesthetic professionals and providing a prescription experience for patients through its pharmacy. RVL Pharmacy dispenses Upneeq only. The Company is also developing Arbaclofen ER tablets for the alleviation of spasticity in multiple sclerosis patients. Its target patient population comprises adults with droopy or low-lying eyelids or acquired ptosis, the majority of whom are female. Its healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and practitioners qualified to diagnose and treat acquired blepharoptosis in adults.
Contact Information
- Headquarters
- 400 Crossing BlvdBRIDGEWATER, NJ, United States 08807-2863
- Phone
- 908-809-1300
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer, Chief Financial Officer
- Brian Markison
- Chief Operating Officer, Executive Vice President
- James Schaub
- Executive Vice President - Research and Development
- Tina deVries
- General Counsel, Secretary
- Christopher Klein
- Director
- Alisa Lask
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $101.3M |
|---|---|
Revenue (TTM) | $49.7M |
Shares Outstanding | 99.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.11 |
EPS | $-0.57 |
Book Value | $0.52 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 2.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -118.64% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
